SG11201810525XA - Anti-gitr antibodies and uses thereof - Google Patents
Anti-gitr antibodies and uses thereofInfo
- Publication number
- SG11201810525XA SG11201810525XA SG11201810525XA SG11201810525XA SG11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new york
- saw mill
- river road
- tarrytown
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/214548 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/036818 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) — 09 June 2017 (09.06.2017) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,353 10 June 2016 (10.06.2016) US 62/432,023 09 December 2016 (09.12.2016) US 62/500,312 02 May 2017 (02.05.2017) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: DELFINO, Frank; c/o Regeneron Pharmaceu- _ ticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). SKOKOS, Dimitris; c/o Regeneron — Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar- = rytown, New York 10591 (US). WANG, Bei; c/o Regen- _ eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). =_ = Agent: CROWLEY-WEBER, Cara, L. et al.; Brownstein = (74) Hyatt Farber Schreck, LLP, 410 Seventeenth Street, Suite 2200, Denver, CO 80202 (US). = = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = _ = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) = — kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — 1-1 GC 71' EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). In 71' 1-1 ei N (54) Title: ANTI-GITR ANTIBODIES AND USES THEREOF 1-1 0 (57) : Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced ei tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662348353P | 2016-06-10 | 2016-06-10 | |
US201662432023P | 2016-12-09 | 2016-12-09 | |
US201762500312P | 2017-05-02 | 2017-05-02 | |
PCT/US2017/036818 WO2017214548A1 (en) | 2016-06-10 | 2017-06-09 | Anti-gitr antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810525XA true SG11201810525XA (en) | 2018-12-28 |
Family
ID=59078260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810525XA SG11201810525XA (en) | 2016-06-10 | 2017-06-09 | Anti-gitr antibodies and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (3) | US10738126B2 (en) |
EP (2) | EP4344748A2 (en) |
JP (2) | JP7162535B2 (en) |
KR (1) | KR102495601B1 (en) |
CN (1) | CN109563170B (en) |
AU (1) | AU2017278193B9 (en) |
BR (1) | BR112018075434A2 (en) |
CA (1) | CA3027121A1 (en) |
CL (1) | CL2018003515A1 (en) |
CO (1) | CO2018013298A2 (en) |
IL (1) | IL263273A (en) |
MA (1) | MA45233A (en) |
MX (2) | MX2018015350A (en) |
PH (1) | PH12018502502A1 (en) |
SG (1) | SG11201810525XA (en) |
WO (1) | WO2017214548A1 (en) |
ZA (1) | ZA201807920B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR097306A1 (en) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | MODULATION OF TUMOR IMMUNITY |
MX2018015350A (en) | 2016-06-10 | 2019-08-26 | Regeneron Pharma | Anti-gitr antibodies and uses thereof. |
IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
CA3040924A1 (en) | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
CR20200465A (en) * | 2018-03-13 | 2020-11-17 | Tust Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
US20220153819A1 (en) | 2019-02-12 | 2022-05-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
RU2734432C1 (en) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody which specifically binds gitr |
KR20210095781A (en) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety |
US11787867B2 (en) * | 2020-03-06 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
CN116761622A (en) * | 2021-01-08 | 2023-09-15 | 苏州丁孚靶点生物技术有限公司 | Pharmaceutical product and use thereof |
TW202237642A (en) * | 2021-01-08 | 2022-10-01 | 美商10X基因組學有限公司 | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
AU760010B2 (en) | 1997-11-18 | 2003-05-08 | Genentech Inc. | DNA19355 polypeptide, a tumor necrosis factor homolog |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
EP1462114A1 (en) | 2003-03-28 | 2004-09-29 | Universiteit Utrecht Holding B.V. | Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
NZ543654A (en) | 2003-05-23 | 2009-05-31 | Wyeth Corp | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
PT2343320T (en) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anti-gitr antibodies and uses thereof |
WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
PT2374818E (en) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
RU2646139C1 (en) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Anti-gitr antibodies |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
CN104126009B (en) | 2011-10-07 | 2019-05-10 | 国立大学法人三重大学 | Chimeric antigen receptor |
KR101549637B1 (en) | 2012-06-08 | 2015-09-03 | 국립암센터 | Novel epitope for switching to Th1 cell and use thereof |
AR097306A1 (en) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | MODULATION OF TUMOR IMMUNITY |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
MA40041B1 (en) | 2014-05-28 | 2021-03-31 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
MX2016015456A (en) | 2014-06-06 | 2017-02-23 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof. |
AU2015327781A1 (en) | 2014-10-03 | 2017-04-20 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
JP6827415B2 (en) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ 5 インコーポレイテッド | Combination therapy for the treatment of the disease |
MX2018015350A (en) | 2016-06-10 | 2019-08-26 | Regeneron Pharma | Anti-gitr antibodies and uses thereof. |
-
2017
- 2017-06-09 MX MX2018015350A patent/MX2018015350A/en unknown
- 2017-06-09 MA MA045233A patent/MA45233A/en unknown
- 2017-06-09 WO PCT/US2017/036818 patent/WO2017214548A1/en unknown
- 2017-06-09 US US15/619,068 patent/US10738126B2/en active Active
- 2017-06-09 BR BR112018075434-0A patent/BR112018075434A2/en unknown
- 2017-06-09 JP JP2018562357A patent/JP7162535B2/en active Active
- 2017-06-09 EP EP23214299.2A patent/EP4344748A2/en active Pending
- 2017-06-09 CA CA3027121A patent/CA3027121A1/en active Pending
- 2017-06-09 AU AU2017278193A patent/AU2017278193B9/en active Active
- 2017-06-09 KR KR1020187036000A patent/KR102495601B1/en active IP Right Grant
- 2017-06-09 CN CN201780048899.6A patent/CN109563170B/en active Active
- 2017-06-09 SG SG11201810525XA patent/SG11201810525XA/en unknown
- 2017-06-09 EP EP17731435.8A patent/EP3468999B1/en active Active
-
2018
- 2018-11-22 ZA ZA2018/07920A patent/ZA201807920B/en unknown
- 2018-11-25 IL IL263273A patent/IL263273A/en unknown
- 2018-11-27 PH PH12018502502A patent/PH12018502502A1/en unknown
- 2018-12-07 CO CONC2018/0013298A patent/CO2018013298A2/en unknown
- 2018-12-07 CL CL2018003515A patent/CL2018003515A1/en unknown
- 2018-12-10 MX MX2022014695A patent/MX2022014695A/en unknown
-
2020
- 2020-06-26 US US16/913,963 patent/US11414494B2/en active Active
-
2022
- 2022-07-13 US US17/812,256 patent/US20230042324A1/en active Pending
- 2022-08-17 JP JP2022130091A patent/JP2022159476A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102495601B1 (en) | 2023-02-06 |
ZA201807920B (en) | 2024-01-31 |
JP2022159476A (en) | 2022-10-17 |
AU2017278193A1 (en) | 2018-12-13 |
CN109563170A (en) | 2019-04-02 |
CA3027121A1 (en) | 2017-12-14 |
EP3468999B1 (en) | 2024-01-10 |
EP3468999A1 (en) | 2019-04-17 |
US10738126B2 (en) | 2020-08-11 |
CO2018013298A2 (en) | 2019-02-19 |
EP4344748A2 (en) | 2024-04-03 |
CL2018003515A1 (en) | 2019-03-08 |
US20230042324A1 (en) | 2023-02-09 |
MA45233A (en) | 2019-04-17 |
MX2022014695A (en) | 2022-12-16 |
JP7162535B2 (en) | 2022-10-28 |
WO2017214548A1 (en) | 2017-12-14 |
IL263273A (en) | 2018-12-31 |
MX2018015350A (en) | 2019-08-26 |
US11414494B2 (en) | 2022-08-16 |
AU2017278193B9 (en) | 2024-02-01 |
CN109563170B (en) | 2023-10-13 |
AU2017278193B2 (en) | 2024-01-18 |
US20210147565A1 (en) | 2021-05-20 |
BR112018075434A2 (en) | 2019-03-19 |
KR20190020297A (en) | 2019-02-28 |
JP2019521098A (en) | 2019-07-25 |
PH12018502502A1 (en) | 2019-04-08 |
US20170355774A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |